People [News in Brief]
Ramon Parsons, MD, PhD, and Miguel Martin, MD, PhD, are highlighted. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
In This Issue [In This Issue]
(Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: In This Issue Source Type: research
HR Intermediates Can Induce Chromosomal Translocations [Translocations]
Multi-invasions (MI) are HR intermediates formed when a ssDNA invades two dsDNA. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Translocations Source Type: research
Inactivating BRAF Mutations Modulate RAS-MAPK Signaling [Signaling]
Hypoactive BRAF mutants bind more tightly to active RAS and amplify ERK signaling. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Signaling Source Type: research
Distinct Tumor-Immune Microenvironments Occur at Different Tumor Sites [Ovarian Cancer]
Tumor regression was linked to immune infiltration in a patient with chemotherapy-treated ovarian cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
The 1q42.1 Risk Allele Promotes Melanoma via PARP1 Upregulation [Melanoma]
An intronic indel variant enhances RECQL binding to upregulate PARP1 in melanocytic cells. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Melanoma Source Type: research
Altered Vasculature in Bone Marrow Drives Leukemogenesis [Leukemia]
Nitric oxide promotes vascular permeability and hypoxia in the bone marrow to drive AML. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
Anti-CTLA4 and Anti-PD-1 Act on Distinct T-cell Populations [Immunotherapy]
Both anti–PD-1 and anti-CTLA4 target subpopulations of exhausted-like CD8+ T cells. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Neural Precursors Drive Glioma Invasion of the Subventricular Zone [Gliomas]
A NPC-derived pleiotrophin promotes glioma invasion into the subventricular zone. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Gliomas Source Type: research
Error-Prone DNA Repair Targets the H3K36me3 Chromatin of Active Genes [Genomics]
Carcinogen-associated error-prone DNA repair increases the mutation rate of active genes in cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Genomics Source Type: research
Epigenetic Repression of LINE-1 Elements Protects Drug-Resistant Cells [Drug Resistance]
H3K9me3–dependent heterochromatin formation maintains drug-tolerant persister (DTP) cell viability. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Drug Resistance Source Type: research
Crizotinib Has Antitumor Activity in ALK-Positive ALCL and IMT [Clinical Trials]
Crizotinib has an overall response rate of 90% in ALCL and 86% in IMT at the recommended phase II dose. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
MAGE-A3-Targeted Autologous CD4+ T Cells May Target Metastatic Cancer [Clinical Trials]
Adoptive transfer of MAGE-A3–targeted CD4+ T cells is safe and achieves responses in several tumor types. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
VEGFR Inhibitor-Resistant Thyroid Cancer Responds to Cabozantinib [Clinical Trials]
Cabozantinib achieved partial responses in 40% of patients with differentiated thyroid cancer (DTC). (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Z-endoxifen Is Active in Endocrine-Refractory Metastatic Breast Cancer [Clinical Trials]
The tamoxifen metabolite Z-endoxifen has acceptable tolerability and antitumor activity. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
